JP2016540042A - がんを処置するためのチェックポイント阻害剤および治療薬の組合せ - Google Patents

がんを処置するためのチェックポイント阻害剤および治療薬の組合せ Download PDF

Info

Publication number
JP2016540042A
JP2016540042A JP2016552469A JP2016552469A JP2016540042A JP 2016540042 A JP2016540042 A JP 2016540042A JP 2016552469 A JP2016552469 A JP 2016552469A JP 2016552469 A JP2016552469 A JP 2016552469A JP 2016540042 A JP2016540042 A JP 2016540042A
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
cells
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540042A5 (OSRAM
Inventor
マルニックス レオ ボッシュ，
マルニックス レオ ボッシュ，
ジェイムズ ケリー ガンジェイ，
ジェイムズ ケリー ガンジェイ，
リンダ エフ． パワーズ，
リンダ エフ． パワーズ，
リンダ エム． リアウ，
リンダ エム． リアウ，
ロバート エム． プリンス，
ロバート エム． プリンス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2016540042A publication Critical patent/JP2016540042A/ja
Publication of JP2016540042A5 publication Critical patent/JP2016540042A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016552469A 2013-11-05 2014-11-05 がんを処置するためのチェックポイント阻害剤および治療薬の組合せ Pending JP2016540042A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361900309P 2013-11-05 2013-11-05
US201361900355P 2013-11-05 2013-11-05
US61/900,309 2013-11-05
US61/900,355 2013-11-05
PCT/US2014/064133 WO2015069770A1 (en) 2013-11-05 2014-11-05 Combinations of checkpoint inhibitors and therapeutics to treat cancer

Publications (2)

Publication Number Publication Date
JP2016540042A true JP2016540042A (ja) 2016-12-22
JP2016540042A5 JP2016540042A5 (OSRAM) 2017-12-14

Family

ID=53042035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552469A Pending JP2016540042A (ja) 2013-11-05 2014-11-05 がんを処置するためのチェックポイント阻害剤および治療薬の組合せ

Country Status (15)

Country Link
US (4) US20150202291A1 (OSRAM)
EP (2) EP3065772B1 (OSRAM)
JP (1) JP2016540042A (OSRAM)
KR (1) KR20160093012A (OSRAM)
CN (1) CN105828834A (OSRAM)
AU (1) AU2014346852A1 (OSRAM)
BR (1) BR112016010224A2 (OSRAM)
CA (1) CA2929407A1 (OSRAM)
EA (1) EA201690912A1 (OSRAM)
ES (1) ES2991853T3 (OSRAM)
HK (1) HK1232119A1 (OSRAM)
IL (3) IL318946A (OSRAM)
MX (2) MX2016005925A (OSRAM)
PH (1) PH12016500841A1 (OSRAM)
WO (1) WO2015069770A1 (OSRAM)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017037059A (ja) * 2015-08-10 2017-02-16 中國醫藥大學附設醫院Ｃｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｈｏｓｐｉｔａｌ 樹状細胞腫瘍ワクチンの適性評価方法及び生存率の予測方法
JP2018521011A (ja) * 2015-05-29 2018-08-02 ダイナバックス テクノロジーズ コーポレイション 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
JP2020510681A (ja) * 2017-03-08 2020-04-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 抗レナラーゼ抗体および抗ｐｄ−１抗体を用いる、がんを処置するための組成物および方法
JP2020522486A (ja) * 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
WO2020246846A1 (ko) * 2019-06-05 2020-12-10 연세대학교 산학협력단 Tox에 기초한 면역 항암 요법에 대한 치료 반응 예측 방법
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
WO2021187922A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
JP2021525765A (ja) * 2018-06-01 2021-09-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬の使用方法
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
JP2022519727A (ja) * 2019-02-08 2022-03-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｓｉｒｔ２除去型キメラｔ細胞
JP2022522328A (ja) * 2019-02-27 2022-04-18 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
JP2022527643A (ja) * 2019-04-03 2022-06-02 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がん治療のための免疫療法
US11780922B2 (en) 2018-02-28 2023-10-10 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
WO2023199927A1 (ja) * 2022-04-13 2023-10-19 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CN107073090A (zh) * 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2016219497A1 (en) * 2015-02-09 2017-08-31 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors and PD-1 inhibitors for treating cancer
BR112017018234A2 (pt) * 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
CA2979388A1 (en) * 2015-03-12 2016-09-15 Health Research, Inc. Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
EP3291821A4 (en) * 2015-05-07 2019-03-20 Baylor College of Medicine IMMUNOTHERAPY WITH DENDRITIC CELLS
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
US10314854B2 (en) * 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
EA201792649A1 (ru) 2015-05-28 2018-06-29 Кайт Фарма, Инк. Способы кондиционирования пациентов для t-клеточной терапии
IL255888B2 (en) * 2015-05-28 2023-03-01 Kite Pharma Inc Diagnostic methods for t-cell therapy
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
KR20240059639A (ko) * 2015-06-01 2024-05-07 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
KR102712880B1 (ko) 2015-06-16 2024-10-02 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
WO2017004532A1 (en) * 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
AU2016291817A1 (en) * 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
JP7032311B2 (ja) * 2015-07-16 2022-03-08 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
DK3328827T3 (da) 2015-07-31 2023-10-02 Univ Johns Hopkins Prodrugs af glutaminanaloger
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017049199A1 (en) * 2015-09-16 2017-03-23 Board Of Regents, University Of Texas System Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
US20180296561A1 (en) * 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
JP6850290B2 (ja) * 2015-10-15 2021-03-31 デューク ユニバーシティー 併用療法
IL309273A (en) * 2015-10-21 2024-02-01 Teclison Ltd Compositions and methods for immune-mediated cancer therapy
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
CA3004138A1 (en) * 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
WO2017079520A1 (en) * 2015-11-04 2017-05-11 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
WO2017079747A1 (en) * 2015-11-06 2017-05-11 Regents Of The University Of Minnesota Activation of resident memory t cells for cancer immunotherapy
CA3004530A1 (en) * 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
KR20250099263A (ko) * 2015-11-20 2025-07-01 메모리얼 슬로안 케터링 캔서 센터 암 치료 방법 및 조성물
KR20180083936A (ko) * 2015-12-01 2018-07-23 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 치료 및 그의 용도 및 방법
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
WO2017096274A1 (en) * 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
KR102699793B1 (ko) * 2016-01-08 2024-08-27 모모타로겐 가부시키가이샤 REIC/Dkk-3 유전자 및 체크포인트 저해제를 이용한 병용 요법
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
US20190022129A1 (en) * 2016-01-08 2019-01-24 Biothera, Inc. Beta-glucan immunotherapies affecting the immune microenvironment
WO2017123643A1 (en) * 2016-01-11 2017-07-20 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
EP3413885A4 (en) * 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
KR102129195B1 (ko) * 2016-02-15 2020-07-01 에프케이디 테라피즈 리미티드, 향상된 인터페론 치료
WO2017145161A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
US10358496B2 (en) * 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
WO2017156483A1 (en) * 2016-03-11 2017-09-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US10869923B2 (en) 2016-03-30 2020-12-22 Microbio Co. Ltd. Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US20190290593A1 (en) 2016-04-29 2019-09-26 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3463398A4 (en) * 2016-05-25 2020-03-11 The Council of the Queensland Institute of Medical Research IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
WO2017212021A1 (en) * 2016-06-10 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR102638898B1 (ko) 2016-08-02 2024-02-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 면역 반응을 조정하기 위한 생체재료
AU2017315468B2 (en) * 2016-08-25 2020-02-13 Nantomics, Llc Immunotherapy markers and uses therefor
CN109906088A (zh) 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
EP3505165B1 (en) * 2016-08-26 2025-11-26 Tetsuji Okuno Method of producing a fine nano-sized medicinal agent
KR20190096936A (ko) 2016-09-15 2019-08-20 이데라 파마슈티칼즈, 인코포레이티드 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정
CA3037253A1 (en) * 2016-09-26 2018-03-29 Advantagene, Inc. Methods of treating tim-3 elevation
KR20240042177A (ko) * 2016-10-05 2024-04-01 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2018065624A1 (en) * 2016-10-07 2018-04-12 Secarna Pharmaceuticals Gmbh & Co Kg Immunosuppression-reverting oligonucleotides inhibiting the expression of ido
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018071837A1 (en) * 2016-10-14 2018-04-19 Baylor College Of Medicine Radiofrequency field hyperthermia and solid tumor immunomodulation
WO2018075447A1 (en) * 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
RU2742726C2 (ru) * 2016-12-09 2021-02-10 Генемедицине Ко., Лтд. Противораковая композиция, содержащая рекомбинантный аденовирус, экспрессирующий разрушающий фактор для внеклеточного матрикса
KR20190134591A (ko) * 2016-12-15 2019-12-04 프로젠 피지500 시리즈 피티와이 리미티드 조성물 및 그의 용도
CA3122548A1 (en) 2016-12-23 2018-06-28 Keio University Compositions and methods for the induction of cd8+ t-cells
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
WO2018147291A1 (en) * 2017-02-07 2018-08-16 Saitama Medical University Immunological biomarker for predicting clinical effect of cancer immunotherapy
CA3052803A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
EP3366703B1 (en) * 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
IL268920B2 (en) * 2017-03-03 2025-05-01 Treos Bio Zrt Peptide vaccines
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN108728440A (zh) * 2017-04-25 2018-11-02 上海吉倍生物技术有限公司 Ctla-4基因的用途及相关药物
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
GB2562721A (en) * 2017-05-16 2018-11-28 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample
WO2019011879A1 (en) * 2017-07-09 2019-01-17 Rainer Henning THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME
US11899017B2 (en) 2017-07-28 2024-02-13 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
US12370256B2 (en) 2017-08-03 2025-07-29 Regents Of The University Of Minnesota Activation of resident memory T cells for the treatment of cancer
EP3668517A4 (en) * 2017-08-14 2021-02-17 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
US20210198364A1 (en) * 2017-09-26 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
CN111372584A (zh) 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Tim-3和pd-1途径的双重抑制剂
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
EP3713548A4 (en) * 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
JP2021517587A (ja) * 2018-01-09 2021-07-26 マイクロバイオ カンパニー， リミテッド 腫瘍浸潤リンパ球（ｔｉｌｓ）を活性化する方法
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CR20250117A (es) 2018-01-26 2025-05-09 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
US11534415B2 (en) 2018-02-02 2022-12-27 Murray And Poole Enterprises Ltd Use of colchicine to inhibit tumor growth and metastases
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019175799A2 (en) 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
EP3773594A4 (en) * 2018-04-05 2021-12-29 Mayo Foundation for Medical Education and Research Materials and methods for treating cancer
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
TWI816603B (zh) 2018-04-23 2023-09-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
EP3566718A1 (en) 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
JP7388635B2 (ja) * 2018-05-31 2023-11-29 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
CA3100216A1 (en) * 2018-06-01 2019-12-05 Tarveda Therapeutics, Inc. Combination therapy
KR20210018229A (ko) 2018-06-08 2021-02-17 해로우 아이피, 엘엘씨 피리메타민-기초된 제약학적 조성물 및 이들을 가공하기 위한 방법
US11266615B2 (en) 2018-06-08 2022-03-08 Harrow Ip, Llc Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
EP3836964A1 (en) * 2018-08-15 2021-06-23 University of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
CN112771067A (zh) * 2018-08-29 2021-05-07 沙塔克实验室有限公司 包含基于SIRPα的嵌合蛋白的组合疗法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3856895A4 (en) * 2018-09-24 2022-08-31 BioVaxys Inc. AUTOLOGOUS BIHAPTENIZED VACCINES AND THEIR USES
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
WO2020091944A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Genomic and immune infiltration differences between msi and mss gi tumors
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3880202A2 (en) * 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
EP3893925A4 (en) * 2018-12-13 2023-01-18 Rhode Island Hospital INHIBITING THE GROWTH AND DEVELOPMENT OF ASPH-EXPRESSING TUMORS
EP3898677A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163628A1 (en) 2019-02-06 2020-08-13 Cornell University Darc expression as prognosticator of immunotherapy outcomes
TW202035702A (zh) 2019-02-20 2020-10-01 學校法人埼玉醫科大學 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記
CN109771445B (zh) * 2019-03-20 2022-08-05 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
CN111751545A (zh) * 2019-03-28 2020-10-09 中国科学院上海药物研究所 一种筛选pd-l1/pd-1检测点抑制剂的方法
EP3721899A1 (en) * 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
US12308095B1 (en) 2019-06-11 2025-05-20 Nantbio, Inc. Prediction of computational pathway circuits
JP7760487B2 (ja) * 2019-06-30 2025-10-27 メモリアル スローン ケタリング キャンサー センター 膵臓癌の処置のための方法および組成物
US11364291B1 (en) * 2019-07-18 2022-06-21 Nantcell, Inc. Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN115151258A (zh) * 2020-01-02 2022-10-04 默沙东有限责任公司 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
JP2023515675A (ja) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
US20250049828A1 (en) * 2021-12-10 2025-02-13 Inxmed (Nanjing) Co., Ltd. Pharmaceutical composition for treating tumors and use
WO2023203561A1 (en) * 2022-04-19 2023-10-26 Enlivex Therapeutics Rdo Ltd Apoptotic cell - check point inhibitor combination therapy
CN117050177B (zh) * 2023-08-25 2024-03-08 遵义北科融汇生命科技有限公司 血液分离的免疫细胞联合药物治疗癌症的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
BRPI0317064B8 (pt) 2002-12-06 2021-05-25 Northwest Biotherapeutics Inc composições compreendendo células dendríticas parcialmente amadurecidas in vitro
GB0406598D0 (en) * 2004-03-24 2004-04-28 Univ Leicester Vaccine
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
NZ582150A (en) * 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
RU2563346C2 (ru) * 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
CA2840170A1 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 66, no. 14, JPN6018032486, 2006, pages 7276 - 7284, ISSN: 0003863896 *
CANCER RES, vol. 69, no. 4, JPN6019015588, 2009, pages 1587 - 1595, ISSN: 0004028645 *
CLIN CANCER RES, vol. 15, no. 19, JPN6018032478, 2009, pages 6267 - 6276, ISSN: 0003863892 *
CLIN CANCER RES, vol. 15, no. 5, JPN6018032482, 2009, pages 1623 - 1634, ISSN: 0003863894 *
CLIN CANCER RES, vol. 16, no. 10, JPN6018032488, 2010, pages 2781 - 2791, ISSN: 0003863897 *
CLIN CANCER RES, vol. 16, no. 24, JPN6019015589, 2010, pages 6019 - 28, ISSN: 0004028646 *
IMMUNOPHARMACOL IMMUNOTOXICOL, vol. 32, no. 2, JPN6018032485, 2010, pages 238 - 245, ISSN: 0003863895 *
J IMMUNOL, vol. 184, no. 7, JPN6019015586, 2010, pages 3442 - 9, ISSN: 0004028643 *
PNAS, vol. 105, no. 8, JPN6018032480, 2008, pages 3005 - 3010, ISSN: 0003863893 *
TARGET ONCOL, vol. 7, no. 1, JPN6018032490, 2012, pages 55 - 68, ISSN: 0003863898 *
実験医学, vol. 31, no. 12, JPN6019015587, 2013, pages 163 - 169, ISSN: 0004028644 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521011A (ja) * 2015-05-29 2018-08-02 ダイナバックス テクノロジーズ コーポレイション 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与
JP2017037059A (ja) * 2015-08-10 2017-02-16 中國醫藥大學附設醫院Ｃｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｈｏｓｐｉｔａｌ 樹状細胞腫瘍ワクチンの適性評価方法及び生存率の予測方法
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
JP2020510681A (ja) * 2017-03-08 2020-04-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 抗レナラーゼ抗体および抗ｐｄ−１抗体を用いる、がんを処置するための組成物および方法
JP7148151B2 (ja) 2017-03-08 2022-10-05 イェール ユニバーシティー 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
JP2020522486A (ja) * 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
JP7503335B2 (ja) 2018-02-09 2024-06-20 慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
JP2022130413A (ja) * 2018-02-09 2022-09-06 慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
US11780922B2 (en) 2018-02-28 2023-10-10 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
JP2021525765A (ja) * 2018-06-01 2021-09-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬の使用方法
JP7346466B2 (ja) 2018-06-01 2023-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬の使用方法
JP2022519727A (ja) * 2019-02-08 2022-03-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｓｉｒｔ２除去型キメラｔ細胞
JP7539896B2 (ja) 2019-02-27 2024-08-26 武田薬品工業株式会社 Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
JP2022522328A (ja) * 2019-02-27 2022-04-18 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
US12419890B2 (en) 2019-02-27 2025-09-23 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
JP2022527643A (ja) * 2019-04-03 2022-06-02 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がん治療のための免疫療法
JP7713390B2 (ja) 2019-04-03 2025-07-25 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がん治療のための免疫療法
WO2020246846A1 (ko) * 2019-06-05 2020-12-10 연세대학교 산학협력단 Tox에 기초한 면역 항암 요법에 대한 치료 반응 예측 방법
US11857601B2 (en) 2020-03-18 2024-01-02 Gi Innovation, Inc. Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
WO2021187922A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
JP2022171109A (ja) * 2021-04-30 2022-11-11 潤 齋藤 Ａｘｌ阻害剤
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
WO2023199927A1 (ja) * 2022-04-13 2023-10-19 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用

Also Published As

Publication number Publication date
IL245337B (en) 2022-05-01
WO2015069770A1 (en) 2015-05-14
EP4461372A3 (en) 2025-01-22
EP3065772A4 (en) 2017-09-13
MX2016005925A (es) 2016-11-28
ES2991853T3 (es) 2024-12-05
US20240358807A1 (en) 2024-10-31
US20150273033A1 (en) 2015-10-01
MX2022006726A (es) 2022-06-09
US20240382572A1 (en) 2024-11-21
EP3065772A1 (en) 2016-09-14
PH12016500841A1 (en) 2016-07-04
EP4461372A2 (en) 2024-11-13
BR112016010224A2 (pt) 2018-05-02
IL318946A (en) 2025-04-01
IL245337A0 (en) 2016-06-30
EP3065772B1 (en) 2024-07-24
AU2014346852A1 (en) 2016-06-16
IL292510A (en) 2022-06-01
KR20160093012A (ko) 2016-08-05
EA201690912A1 (ru) 2016-10-31
US20150202291A1 (en) 2015-07-23
CA2929407A1 (en) 2015-05-14
HK1232119A1 (zh) 2018-01-05
CN105828834A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
US20240358807A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
Muth et al. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma
US20230414540A1 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
US20250313803A1 (en) Compositions and Methods for Cancer Immunotherapy
JP2020114837A (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
AU2018360386B2 (en) Dual inhibitors of TIM-3 and PD-1 pathways
US11986538B2 (en) Immunoswitch nanoparticles for reprogrammed T cell responses
EP3532076B1 (en) Immunotherapeutic treatments for tumours
JP2021523098A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
JP7407452B2 (ja) がんの治療及び／又は予防のための医薬
HK40033024A (en) Compositions and methods for cancer immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200205